ClinicalTrials.gg
Active, not recruitingNCT07134088Updated Oct 5, 2026

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

A Phase 1/2 interventional study of Blinatumomab in Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia, sponsored by Amgen. Active, not recruiting at 5 sites in 2 countries. Open to participants aged 28 Days and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Primary conditionNeoplasm, ResidualRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasm, Residual
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Neoplasm, Residual.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Updated Oct 5, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
104
Allocation
Non-randomized
Ages
28 Days and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing blinatumomab in Neoplasm, Residual — 3 open to participants now, 6 under way, none of them phase 3. blinatumomab · Neoplasm, Residual.

Planned enrollment
6th of 17
104 · median 31
Started
2025
with 2 others
Phase 1/2
3 of 17
none open now
Registered
17th of 17
by date
Lead sponsor
3 of 17
Amgen

Among the 17 studies testing blinatumomab in Neoplasm, Residual, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is one of 3 in phase 1/2, and was the 17th registered.

Neoplasm, Residual

293 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.

Browse Neoplasm, Residual studies →

Open to participants now

3 of the 17 studies testing blinatumomab in Neoplasm, Residual are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Neoplasm, Residual studies recruiting now, 58 (63%) set no upper age limit and 23 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.

This study: 28 Days and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing blinatumomab in Neoplasm, Residual, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.

03

Conditions studied

  • Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
  • Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia

Browse trials for

Keywords

  • Blinatumomab
  • AMG 103
  • Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
  • Minimal Residual Disease Positive B-Cell Precursor Acute Lymphoblastic Leukemia
  • R/R B-ALL
  • MRD+ B-ALL
04

In context

Neoplasm, Residual Reclassified

293 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.

This study's planned enrollment of 104 is above the median of 50 across 198 interventional studies indexed under Neoplasm, Residual.

Browse Neoplasm, Residual studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Neoplasm, Residual, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
28 Days and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥28 days to \<12 years at the time of /assent.
  • Lansky Performance Status (LPS) of ≥ 50%.
  • For Phase 1b and Phase 2 cohort in participants with R/R B-ALL:

    • Participants with B-ALL after or refractory to any including hematopoietic stem cell transplant (HSCT).
    • Greater than or equal to 5% blasts in the bone marrow (BM) is considered as relapse in the BM.
  • For Phase 2 cohort in participants with MRD+ B-ALL:

    • Participants with MRD+ B-ALL must have between ≥ 0.1% and \< 5% blasts in the BM.
  • Prior CD19-directed therapy will be allowed (with demonstrated continued CD19+ expression) if treatment ended >4 weeks prior to start of protocol therapy and no prior central nervous system (CNS) complications.
  • Any Philadelphia chromosome-positive (Ph+) participant intolerant or refractory to prior tyrosine kinase inhibitors (TKIs) are eligible.

Exclusion criteria

Exclusion Criteria:

  • Active ALL in the CNS.
  • History or presence of CNS pathology or event such as epilepsy, childhood seizure, paresis, aphasia, stroke, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis, or severe (≥ grade 3) CNS events including immune effector cell-associated neurologic syndrome (ICANS) from prior CAR-T or other T-cell engager therapies.
  • Isolated EM disease.
  • Current disease or history of autoimmune disease with potential CNS involvement.
  • Patients with Down Syndrome are not eligible for this study.
  • Active acute or chronic requiring systemic treatment with medication.
  • Known infection with (HIV) or chronic infection with virus or virus.
  • Presence of an acute or uncontrolled chronic infection, or any other concurrent disease or medical condition that could be worsened by the treatment or interfere with the participant's ability to comply with the study protocol.
  • HSCT within 12 weeks before the start of blinatumomab.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Phase 1b: R/R B-ALL

    Participants with R/R B-ALL will receive blinatumomab as SC injection to determine the pediatric recommended Phase 2 dose (RP2D).

    Drug: Blinatumomab

  • Experimental
    Cohort Ph2-R

    Participants with R/R B-ALL will receive blinatumomab as SC injection at RP2D.

    Drug: Blinatumomab

  • Experimental
    Cohort Ph2-M

    Participants with MRD+ B-ALL will receive blinatumomab as SC injection at RP2D.

    Drug: Blinatumomab

Interventions

  • Blinatumomab will be administered as a SC injection for up to 5 cycles (each cycle will be 35 days).

07

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants who Experienced Dose Limiting Toxicities (DLTs)

    Time frame: Up to 29 days

  2. Phase 1b: Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 7 months

  3. Phase 1b: Number of Participants who Experienced Serious TEAEs

    Time frame: Up to 2 years and 7 months

  4. Phase 1b: Number of Participants who Experienced Treatment-related TEAEs

    Time frame: Up to approximately 7 months

  5. Phase 1b: Number of Participants who Experienced AEs of Interest (EOI)

    Time frame: Up to approximately 7 months

  6. Phase 2; R Cohort: Number of Participants who had Complete Remission/Complete Remission with Partial Hematological Recovery (CR/CRh) Within the First 2 Cycles

    Time frame: Up to 70 days

  7. Phase 2; M Cohort: Number of Participants who had CR with MRD Negative Response Within the First 2 Cycles

    MRD negative response = MRD level \< 10\^-4 (0.01%).

    Time frame: Up to 70 days

Secondary outcomes

  1. Phase 1b: Number of Participants who had CR/CRh Within the First 2 Cycles

    Time frame: Up to 70 days

  2. Phase 1b: Number of Participants who had CR Within the First 2 Cycles

    Time frame: Up to 70 days

  3. Phase 1b: Number of Participants who had CR/CRh/Complete Remission with Incomplete Hematological Recovery (CRi) or Blast Free Hypoplastic or Aplastic Bone Marrow (BM) Within the First 2 Cycles

    Time frame: Up to 70 days

  4. Phase 1b: Number of Participants with a MRD Negative Response Within the First 2 Cycles

    MRD negative response = MRD level \< 10\^-4 (0.01%).

    Time frame: Up to 70 days

  5. Phase 1b: Duration of Response (DOR)

    DOR is defined as the time from the first response of CR/CRh within the first 2 cycles until hematological relapse (Including extramedullary \[EM\] relapse) per investigator's assessment or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years and 7 months

  6. Phase 1b: Maximum Concentration (Cmax) of Blinatumomab

    Time frame: Up to approximately 7 months

  7. Phase 1b: Time to Maximum Concentration (Tmax)

    Time frame: Up to approximately 7 months

  8. Phase 1b: Area Under the Concentration Time Curve (AUC)

    Time frame: Up to approximately 7 months

  9. Phase 1b: Number of Participants with Anti-blinatumomab Antibodies

    Time frame: Cycle 1, Day 1 and Cycle 2, Day 1 (Cycle Duration = 35 days)

  10. Phase 2: Number of Participants who had CR/CRh with MRD Negative Response Within the First 2 Cycles

    MRD negative response = MRD level \< 10\^-4 (0.01%).

    Time frame: Up to 70 days

  11. Phase 2: DOR

    DOR is defined as the time from the first response of CR/CRh within the first 2 cycles until hematological relapse (Including EM relapse) per investigator's assessment or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years and 7 months

  12. Phase 2; R Cohort: Number of participants who had CR Within the First 2 Cycles

    Time frame: Up to 70 days

  13. Phase 2; R Cohort: Number of participants who had CR/CRh/CRi and Blast Free Hypoplastic or Aplastic BM Within the First 2 Cycles

    Time frame: Up to 70 days

  14. Phase 2: Overall Survival (OS)

    OS is defined as the time from the first dose until death due to any cause.

    Time frame: Up to 2 years and 7 months

  15. Phase 2: Number of Participants who Experienced TEAEs, Serious TEAEs, Treatment Related TEAEs and EOIs

    Time frame: Up to 2 years and 7 months

  16. Phase 2: Blinatumomab Serum Concentrations

    Time frame: Up to 175 days

  17. Phase 2: Number of Participants with Anti-blinatumomab Antibodies

    Time frame: Cycle 1, Day 1 and Cycle 2, Day 1 (Cycle Duration = 35 days)

  18. Phase 2; M Cohort: Number of participants who had CR/CRh/CRi and Blast Free Hypoplastic or Aplastic BM with MRD Negative Response Within the First 2 Cycles

    MRD negative response = MRD level \< 10\^-4 (0.01%).

    Time frame: Up to 70 days

08

Study locations

5 sites
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Mar 2031, 62 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Dec 2028 → Mar 2031 and completion Jun 2030 → Sep 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Dec 8, 2025
Primary completionEst.
Mar 6, 2031was Dec 2028
CompletionEst.
Sep 16, 2032was Jun 2030
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 5, 2028→Mar 6, 2031
Oct 5, 2026
Study completion
Jun 18, 2030→Sep 16, 2032
Oct 5, 2026
Eligibility
Maximum age 4383 Days→none
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Dec 5, 2028→Mar 6, 2031
    Study completion Jun 18, 2030→Sep 16, 2032
    Eligibility Maximum age 4383 Days→none
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07134088
Lead sponsor
Amgen
Collaborators
BeOne Medicines
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Dec 8, 2025
Primary completion
Mar 6, 2031 (estimated)
Completion
Sep 16, 2032 (estimated)
Last update
Oct 5, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion